2. Search Result
Search Result
Results for "

switchable

" in MedChemExpress (MCE) Product Catalog:

55

Inhibitors & Agonists

2

Fluorescent Dye

2

Biochemical Assay Reagents

2

Peptides

10

Inhibitory Antibodies

5

Natural
Products

3

Click Chemistry

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W030319
    Methyl 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetate

    		Fluorescent Dye Others
    Methyl 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetate, a natural coumarins derivative, is exploited for the synthesis of the switchable fluorescent substrates to be used in bacterial enzyme detection .
    Methyl 2-(7-hydroxy-2-oxo-2H-chromen-4-yl)acetate
  • HY-112306
    Ripretinib
    5 Publications Verification

    DCC-2618

    		 c-Kit PDGFR FLT3 VEGFR Apoptosis Cancer
    Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
    Ripretinib
  • HY-16046
    Rimiducid
    Maximum Cited Publications
    47 Publications Verification

    AP1903

    		 FKBP Apoptosis Cancer
    Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.
    Rimiducid
  • HY-U00451
    ATP-Red 1
    5+ Cited Publications

    		 Fluorescent Dye Others
    ATP-Red 1 is a multisite-binding switchable fluorescent probe, and can selectively and rapidly responds to intracellular concentrations of ATP in living cells (Ex/Em = 510/590 nm).
    ATP-Red 1
  • HY-U00451Y
    ATP-Red 1 (solution)
    5+ Cited Publications

    		 Fluorescent Dye Others
    ATP-Red 1 (solution) is a multisite-binding switchable fluorescent probe, and can selectively and rapidly responds to intracellular concentrations of ATP in living cells (Ex/Em = 510/590 nm).
    ATP-Red 1 (solution)
  • HY-126247
    BI-2852

    		Ras Cancer
    BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
    BI-2852
  • HY-146116
    Antifungal agent 32

    		Fungal Infection
    Antifungal agent 32 (compound 1a) is a potent antifungal agent. Antifungal agent 32 inhibits Candida albicans filamentation and biofilm formation. Antifungal agent 32 inhibits the morphological switching of Candida albicans and its adherence to epithelial cells. Antifungal agent 32 can be used for Candida albicans infections research .
    Antifungal agent 32
  • HY-160209
    KIO-301

    		HCN Channel Cardiovascular Disease
    KIO-301 is a photoswitchable HCN channel blocker, and can be used as the vitreous “light switch” molecule that reactivates retinitis pigmentosa .
    KIO-301
  • HY-112306R
    Ripretinib (Standard)

    		c-Kit PDGFR FLT3 VEGFR Apoptosis Cancer
    Ripretinib (Standard) is the analytical standard of Ripretinib. This product is intended for research and analytical applications. Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
    Ripretinib (Standard)
  • HY-161066
    KRAS G13D-IN-1

    		Ras Cancer
    KRAS G13D-IN-1 (compound 41) is a selective and covalently reversible inhibitor of KRAS G13D (IC50: 0.41 nM). The selectivity for KRAS G13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRAS G13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades .
    KRAS G13D-IN-1
  • HY-N15775
    Ace-1

    		Biochemical Assay Reagents Others
    ACe-1 is a ceramide derivative with an azobenzene moiety to allow for optical control of the N-acyl chain. ACe-1 is capable of reversibly switching lipid domains in a raft-like bilayer membrane .
    Ace-1
  • HY-N15781
    Trans-faazo-4

    		Biochemical Assay Reagents Metabolic Disease
    Trans-FAAzo-4 is a photo-switchable fatty acid analogue used in photo-pharmacology. Trans-FAAzo-4 is able to alter membrane lateral pressure and thus control opening and closing of mechanosensitive ion channels .
    Trans-faazo-4
  • HY-170747
    9-tert-Butyldoxycycline

    		Bacterial Infection Inflammation/Immunology
    9-tert-Butyldoxycycline exhibits immunomodulatory activity, alters the polarization states polymorphonuclear neutrophils, and ameliorates the inflammatory response in ischemia-reperfusion injury model. 9-tert-Butyldoxycycline is the ligand for ‘Tet-On’ switch system .
    9-tert-Butyldoxycycline
  • HY-174677
    Human GATA1 mRNA

    		mRNA Cancer
    Human GATA1 mRNA encodes the human GATA binding protein 1 (GATA1) which belongs to the GATA family. GATA1 plays an important role in erythroid development by regulating the switch of fetal hemoglobin to adult hemoglobin.
    Human GATA1 mRNA
  • HY-119990
    Fotocaine

    		Biochemical Assay Reagents Neurological Disease Inflammation/Immunology
    Fotocaine is a photochromic blocker of voltage-gated ion channels. Fotocaine is readily taken up by neurons in brain slices and enables optical control of action potential firing by switching between 350 and 450 nm light. Fotocaine can be used in analgesia research .
    Fotocaine
  • HY-N15785
    18:0-Azo PC

    		Biochemical Assay Reagents Metabolic Disease
    18:0-azo PC is an analog of phosphatidylcholine (PC). Under light, 18:0-azo PC can be switched on and off by light, forcing the azobenzene portion of the molecule to undergo cis/trans isomerization, leading to the initiation or termination of cell signaling.
    18:0-Azo PC
  • HY-157261
    UNC2383

    		Biochemical Assay Reagents Endocrinology
    UNC2383 is an oligonucleotide enhancer compound. UNC2383 can enhance the efficacy of antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs). UNC2383 can be used in research of diseases involving impaired oligonucleotide delivery, such as cystic fibrosis .
    UNC2383
  • HY-126247B
    (R)-BI-2852

    		Drug Derivative Ras Cancer
    (R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.
    (R)-BI-2852
  • HY-120897
    NS-3-008 hydrochloride

    		Bcl-2 Family Apoptosis Inflammation/Immunology
    NS-3-008 hydrochloride is an orally active transcriptional inhibitor of G0/G1 switch 2 (G0s2) with an IC50 of 2.25 μM. NS-3-008 hydrochloride can be used for chronic kidney disease .
    NS-3-008 hydrochloride
  • HY-145928
    Divarasib
    4 Publications Verification

    GDC-6036

    		 Ras Cancer
    Divarasib (GDC-6036) is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds to the switch II (SW-II) pocket of KRAS G12C and irreversibly locks it in the inactive GDP-bound state.
    Divarasib
  • HY-125667
    PA1

    Photoamiloride-1

    		 Sodium Channel Metabolic Disease
    PA1 is a photoswitchable epithelial sodium channel (ENaC) blocker. PA1 can switch to cis-PA1 at 400nm and trans-PA1 at 500nm. PA1 inhibits δ/αENaC, αβγENaC, and δβγENaC, with IC50 values of 4.3nM, 90 nM, and 390 nM, respectively .
    PA1
  • HY-145928B
    Divarasib adipate
    4 Publications Verification

    GDC-6036 adipate

    		 Ras Cancer
    Divarasib (GDC-6036) adipate is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds to the switch II (SW-II) pocket of KRAS G12C and irreversibly locks it in the inactive GDP-bound state .
    Divarasib adipate
  • HY-148905
    p-Aminophenylmercuric acetate
    4 Publications Verification

    		 Cathepsin MMP Infection
    p-Aminophenylmercuric acetate is an organomercurial activator of matrix metalloproteinases (MMP). P-Aminophenylmercuric acetate participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl or inducing cysteine switching reaction. p-Aminophenylmercuric acetate promotes the shedding of betacellulin precursor (pro-BTC). p-Aminophenylmercuric acetate influences the binding of agonists and antagonists to the opiate receptor .
    p-Aminophenylmercuric acetate
  • HY-P11315
    MG1 peptide

    		Biochemical Assay Reagents Neurological Disease
    MG1 peptide is a M1 Microglia-targeting peptide. MG1 peptide can conjugate to anoparticles, crossing the BBB to precisely M1 microglia recognition and achieving controlled release and specific accumulation of drugs through intelligent molecular switching. MG1 peptide can be used for drug delivery for ischemic stroke research .
    MG1 peptide
  • HY-N0284
    Esculetin
    5 Publications Verification

    		 PI3K Akt Inflammation/Immunology Cancer
    Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities .
    Esculetin
  • HY-174613
    Human IL27 mRNA

    		mRNA Inflammation/Immunology
    Human IL27 mRNA encodes the human interleukin 27 (IL27) protein, one of the subunits of a heterodimeric cytokine complex. IL-27 has pro- and anti-inflammatory properties, that can regulate T-helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity and induce isotype switching in B-cells.
    Human IL27 mRNA
  • HY-100825
    OABK hydrochloride

    		Biochemical Assay Reagents Others
    OABK hydrochloride is a small-molecule switch that can be used to control protein activity. OABK (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    OABK hydrochloride
  • HY-174738
    Human CD40 mRNA

    		mRNA Inflammation/Immunology
    Human CD40 mRNA encodes the human CD40 molecule (CD40) protein, a member of the TNF-receptor superfamily. CD40 is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation.
    Human CD40 mRNA
  • HY-P99313
    Quilizumab

    Anti-Human IGHE Recombinant Antibody

    		 Apoptosis Inflammation/Immunology
    Quilizumab (Anti-Human IGHE Recombinant Antibody) is a humanized IgG1κ monoclonal antibody targeting immunoglobulin epsilon (also konwn as: IGHE, IgE). Quilizumab targets the M1-prime fragment of membrane-expressed IGHE/IgE, leading to IGHE/IgE switching and memory B cell depletion. Quilizumab has potential in asthma research .
    Quilizumab
  • HY-13868
    SCH-53870

    		Ras Cancer
    SCH-53870 is a Ras activation inhibitor that binds to the Ras-GDP complex, keeping the Ras protein in an inactive GDP-bound state and preventing it from switching to an active GTP-bound state. SCH-53870 affects cell signaling and cell proliferation by preventing the activation of Ras protein. SCH-53870 can be used in cancer research .
    SCH-53870
  • HY-107712
    TCN 213

    		iGluR Neurological Disease
    TCN 213 is a selective, surmountable, glycine-dependentlly GluN1/GluN2A NMDAR antagonist with IC50s of 0.55, 3.5, 40 μM in the presence of 75, 750, 7500 nM glycine, respectively. TCN 213 can be used to monitor, pharmacologically, the switch in NMDAR expression in developing cortical neurones .
    TCN 213
  • HY-103713
    Seclidemstat
    5+ Cited Publications

    SP-2577

    		 Histone Demethylase Cancer
    Seclidemstat is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat can be used for the research of Ewing Sarcoma .
    Seclidemstat
  • HY-164645
    pan-KRAS-IN-16

    		Ras Cancer
    pan-KRAS-IN-16 (Compound 3344) is an anti-RAS small molecule derived from an intracellular antibody fragment with pan-RAS-effector protein-protein interaction inhibitor properties. pan-KRAS-IN-16 binds to a hydrophobic pocket near to the effector-binding switch regions of RAS. pan-KRAS-IN-16 prevents endogenous RAS-dependent signaling in tumor cell lines .
    pan-KRAS-IN-16
  • HY-103713A
    Seclidemstat mesylate
    5+ Cited Publications

    SP-2577 mesylate

    		 Histone Demethylase Cancer
    Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma .
    Seclidemstat mesylate
  • HY-N0284R
    Esculetin (Standard)

    		Reference Standards PI3K Akt Inflammation/Immunology Cancer
    Esculetin (Standard) is the analytical standard of Esculetin. This product is intended for research and analytical applications. Esculetin is an active ingredient extracted mainly from the bark of Fraxinus rhynchophylla. Esculetin inhibits platelet-derived growth factor (PDGF)-induced airway smooth muscle cells (ASMCs) phenotype switching through inhibition of PI3K/Akt pathway. Esculetin has antioxidant, antiinflammatory, and antitumor activities .
    Esculetin (Standard)
  • HY-P99236
    Bexmarilimab
    1 Publications Verification

    FP-1305

    		 Transmembrane Glycoprotein Inflammation/Immunology Cancer
    Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .
    Bexmarilimab
  • HY-151523
    KRas G12R inhibitor 1

    		Ras Cancer
    KRas G12R inhibitor 1 is a covalent inhibitor targeting the common oncogenic mutant KRas G12R with selectivity for the mutant arginine. KRas G12R inhibitor 1 possesses an α,β-diketoamide and exploits strong nucleophilicity of the mutant cysteine and irreversibly binds in the Switch II region of KRas. KRas G12R inhibitor 1 can be researched for K-Ras (G12R)-driven cancer such as pancreatic ductal adenocarcinoma (PDAC) .
    KRas G12R inhibitor 1
  • HY-173350
    Ran-IN-1

    		Arf Family GTPase Apoptosis Cancer
    Ran-IN-1 (Compound M36) is an orally active and selective Ran GTPase inhibitor. Ran-IN-1 binds to the GDP-bound form of Ran (RanGDP) at the allosteric switch II pocket with high specificity, stabilizing the inactive state and reducing the active Ran-GTP population. Ran-IN-1 induces apoptosis and represses DNA repair pathways like HR and NHEJ in epithelial ovarian cancer (EOC) cells. Ran-IN-1 is promising for research of EOC, particularly high-grade serous carcinoma .
    Ran-IN-1
  • HY-172760
    CIM-834

    		Virus Protease SARS-CoV Infection
    CIM-834 is an orally active and selective inhibitor targeting the coronavirus membrane protein (M protein), which potently blocks viral assembly against SARS-CoV-2 and SARS-CoV. CIM-834 binds to the short form of the M protein (Mshort) in a non-covalent manner, stabilizing Mshort and preventing its conformational switch to the long form (Mlong) required for virion assembly, thereby inhibiting viral particle formation. CIM-834 is promising for research of COVID-19 and other coronavirus infections .
    CIM-834
  • HY-128522
    ARS-1323-alkyne

    		Ras Cancer
    ARS-1323-alkyne is a covalent inhibitor probe that covalently binds to the Switch-II pocket (S-IIP) of the KRAS G12C mutant protein. ARS-1323-alkyne visualizes the covalent modification of KRAS G12C and quantitatively measures the binding efficiency of the inhibitor to the target. ARS-1323-alkyne can be used to validate the target occupancy of KRAS G12C inhibitors and the synergistic mechanism of combination therapy, providing tool support for the development of combination treatment strategies .
    ARS-1323-alkyne
  • HY-I0259
    8-Amino-2-naphthol

    		Fluorescent Dye Others
    8-Amino-2-naphthol is a photoactive charge transfer compounds, which can be used as fluorescent probe. 8-Amino-2-naphthol undergoes excited-state proton transfer (ESPT) to form a zwitterion under acidic conditions, where the photoacidity of its hydroxyl group is regulated by the protonation state of the amino group, enabling pH to act as an on/off switch for photoacidity. 8-Amino-2-naphthol is also utilized as chiral organocatalyst .
    8-Amino-2-naphthol
  • HY-175180
    Conophyllidine

    		Histone Acetyltransferase Arginase Inflammation/Immunology Cancer
    Conophyllidine, a bisindole alkaloid, is a selective M2 polarization inhibitor. Conophyllidine inhibits histone acetylation by targeting the histone acetyltransferase domain of the P300/CBP proteins. Conophyllidine inhibits IL-4-induced arginase with an IC50 of 0.31 μM. Conophyllidine effectively induces a phenotypic switch in tumor-associated macrophages (TAMs) from an anti-inflammatory to an inflammatory type, thereby enhancing cytotoxic CD8 + T cell recruitment and functionality within the tumor microenvironment. Conophyllidine can be used for the study of TAMs .
    Conophyllidine
  • HY-124798
    Rheb inhibitor NR1
    3 Publications Verification

    		 mTOR Neurological Disease Inflammation/Immunology Cancer
    Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven T389pS6K1 and increases the phosphorylation of S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity .
    (Rheb-IVK: Rheb-dependent mTORC1 kinase activity)
    Rheb inhibitor NR1
  • HY-134813A
    MRTX1133 formic

    		Ras Cancer
    MRTX1133 formic is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 formic prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRASG12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 formic shows efficacy in tumor models harboring KRAS G12D mutations .
    MRTX1133 formic
  • HY-P11108
    RP-182

    		NF-κB Apoptosis TNF Receptor Caspase Inflammation/Immunology Cancer
    RP-182 is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 (Kd = 8 μM) on the surface of tumor-associated macrophages (TAMs). RP-182 induces a conformational switch of the CD206 receptor, which activates NF-κB signaling and phagocytosis in CD206 high TAMs. RP-182 has dual function: activation of canonical NF-κB signaling, triggering TNFα secretion and autocrine activation of the TNF receptor 1 (TNFR1), leading to activation of caspase 8, apoptosis, and cell death. RP-182 is used in pancreatic cancer and melanoma research .
    RP-182
  • HY-161577
    BFC1103

    		Bcl-2 Family Cancer
    BFC1103 is a small-molecule compound whose primary mechanism of action involves interaction with a specific domain of Bcl-2, particularly its loop domain. This interaction induces a conformational change in Bcl-2, exposing its BH3 (Bcl-2 homology 3) domain, thereby switching Bcl-2's function from anti-apoptotic to pro-apoptotic. The cell death induced by BFC1103 is dependent on the presence of Bax or Bak, both of which are key proteins involved in the intrinsic apoptotic pathway mediated by mitochondria. BFC1103 has successfully inhibited lung metastasis of triple-negative breast cancer in mouse models. It can be utilized in studying the roles of Bcl-2 family proteins in cancer development and how they impact the survival and proliferation of cancer cells .
    BFC1103
  • HY-134813
    MRTX1133
    30+ Cited Publications

    		 Ras Cancer
    MRTX1133 is a noncovalent, potent, and selective alkyne-based KRAS G12D inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 selectively inhibits KRAS G12D mutant, but not KRAS wild-type, tumor cells. MRTX1133 has single digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations .
    MRTX1133
  • HY-P990304A
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a)

    		TNF Receptor Infection Inflammation/Immunology Cancer
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) is a mouse-derived IgG2a κ antibody inhibitor that targets mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG2a. Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a) can be used for the researches of cancer, infection, inflammation and immunology.
    Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-Mouse IgG2a)
  • HY-P990269
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)

    		TNF Receptor Inflammation/Immunology Cancer
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse CD40L/CD154. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a chimeric version of the original MR-1 antibody (HY-P990134). The variable domain sequences are identical to the original MR-1 but the constant region sequences have been switched from Armenian hamster IgG to mouse IgG2a. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) contains a LALA-PG mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) blocks CD40/CD40L signaling. Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) can be used for researches of cancer, inflammation and immunology.
    Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)
  • HY-P990304B
    Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1)

    		TNF Receptor Infection Inflammation/Immunology Cancer
    Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a mouse-derived IgG1 κ antibody inhibitor that targets mouse 4-1BBL/CD137L. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is a chimeric version of the original TKS-1 antibody (HY-P990304). The variable domain sequences are identical to the original TKS-1 but the constant region sequences have been switched from rat IgG2a to mouse IgG1. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) contains a D265A mutation in the Fc fragment rendering it unable to bind to endogenous Fcγ receptors. Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) reacts with mouse 4-1BB ligand (4-1BBL). Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) can be used for the researches of cancer, infection, inflammation and immunology.
    Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: